1. Home
  2. BVS vs STTK Comparison

BVS vs STTK Comparison

Compare BVS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

N/A

Current Price

$13.45

Market Cap

929.6M

Sector

Health Care

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$6.84

Market Cap

792.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BVS
STTK
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
929.6M
792.9M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
BVS
STTK
Price
$13.45
$6.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
★ $17.60
$14.67
AVG Volume (30 Days)
408.8K
★ 864.5K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 163.46
53.02
EPS
★ 0.52
N/A
Revenue
★ $568,087,000.00
$1,000,000.00
Revenue This Year
$6.46
N/A
Revenue Next Year
$6.74
N/A
P/E Ratio
$26.91
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$6.37
$1.70
52 Week High
$15.89
$8.33

Technical Indicators

Market Signals
Indicator
BVS
STTK
Relative Strength Index (RSI) 52.37 60.14
Support Level $13.44 $6.75
Resistance Level $14.71 $7.75
Average True Range (ATR) 0.44 0.39
MACD 0.04 0.12
Stochastic Oscillator 75.14 90.10

Price Performance

Historical Comparison
BVS
STTK

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: